Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Perrigo
|
| gptkbp:acquisitionYear |
2013
|
| gptkbp:country |
gptkb:Ireland
|
| gptkbp:focus |
autoimmune diseases
neurological diseases |
| gptkbp:founded |
1969
|
| gptkbp:founder |
gptkb:Donal_Geaney
|
| gptkbp:headquarters_location |
gptkb:Dublin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elan Corporation
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Prialt
gptkb:Tysabri |
| gptkbp:numberOfEmployees |
~200 (2013)
|
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:Irish_Stock_Exchange
gptkb:New_York_Stock_Exchange |
| gptkbp:tradedOn |
ISEQ: ELN
NYSE: ELN |
| gptkbp:website |
www.elan.com
|
| gptkbp:bfsParent |
gptkb:PRGO
gptkb:Don_Panoz |
| gptkbp:bfsLayer |
7
|